Brief: Ryvu Therapeutics Signs Two Deals On RVU120

Ryvu Therapeutics SA

06/07/2023 07:38

July 6 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * SIGNS TWO DEALS WITH ZAKŁADY FARMACEUTYCZNE POLPHARMA ON
PRODUCTION OF API FOR RVU120 MEDICATION
    * FIRST DEAL VALUE AT ABOUT EUR 0.89 MILLION, SECOND DEAL
VALUE AT
ABOUT EUR 0.77 MILLION
    * SECOND PHASE OF CLINICAL TRIALS IN HEMATOLOGICAL
INDICATIONS FOR
RVU120 SET FOR H2
    * RVU120 MEDICATION TARGETS ACUTE MYELOID LEUKEMIA/HIGH-RISK
MYELODYSPLASTIC SYNDROME (AML/HR-MDS)

Source text for Eikon:  ID:nEM5YXlLWa 
Further company coverage:  RVU.WA 

 (Reporting by Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))